By consensus report of the American Diabetes Association and the European Association of the Study of Diabetes published in 2018, SGLT2 inhibitors were suggested to be the first consideration for use in DM patients with cardiovascular disease and heart failure [13]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.